Zenlabs Ethica

how big is Zenlabs Ethica?

As of Jun 06, Zenlabs Ethica Ltd has a market capitalization of 21.71 Cr, with net sales of 51.42 Cr and a net profit of 0.27 Cr over the latest four quarters. The standalone balance sheet as of Mar'24 shows shareholder's funds of 10.12 Cr and total assets of 39.98 Cr.

As of Jun 06, Zenlabs Ethica Ltd has a market capitalization of 21.71 Cr, categorizing it as a Micro Cap company.<BR><BR>As of Jun 06, the company's Net Sales for the latest four quarters, which include Mar'25, Dec'24, Sep'24, and Jun'24, total 51.42 Cr. The Net Profit for the same period is 0.27 Cr. This data is presented on a Standalone basis.<BR><BR>As of Mar'24, the Standalone balance sheet shows Shareholder's Funds amounting to 10.12 Cr and Total Assets of 39.98 Cr.

What does Zenlabs Ethica do?

Zenlabs Ethica Ltd is a pharmaceutical contract marketing and trading company, categorized as a micro-cap with a market cap of Rs 21 Cr. As of March 2025, it reported net sales of 13 Cr and a net profit of 0 Cr.

Overview: <BR>Zenlabs Ethica Ltd is a pharmaceutical contract marketing and trading company that operates in the diversified commercial services industry, categorized as a micro-cap company.<BR><BR>History: <BR>Zenlabs Ethica Limited, formerly known as Neelkanth Technologies Limited, was incorporated in 1993. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 13 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap: Rs 21 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.22 <BR>Return on Equity: 2.59% <BR>Price to Book: 2.04<BR><BR>Contact Details: <BR>Address: Plot No 194-195 3rd Flr Pha-II, Industrial Area Ram Darbar Chandigarh Chandigarh ( U T ) : 160002 <BR>Tel: 91-172-4651105/3920738 <BR>Email: queries@zenlabsethica.com <BR>Website: http://www.zenlabsindia.com; www.zenlabsethica.com

When is the next results date for Zenlabs Ethica?

No Upcoming Board Meetings

What is the bonus history of the Zenlabs Ethica?

Zenlabs Ethica's bonus history includes a 1:20 bonus share announcement on October 11, 2018, with a record date of October 13, 2018, meaning shareholders received 1 additional share for every 20 shares held.

Zenlabs Ethica has a bonus history that includes a notable issue on October 11, 2018. The company announced a bonus in the ratio of 1:20, which means that for every 20 shares held, shareholders received 1 additional share. The record date for this bonus was October 13, 2018. If you have any more questions about Zenlabs Ethica or need further details, feel free to ask!

Has Zenlabs Ethica declared dividend?

Zenlabs Ethica Ltd has declared a 2% dividend, amounting to 0.2 per share, with an ex-date of July 29, 2022. However, the total returns over various periods have been negative, and the dividend yield remains at 0%.

Zenlabs Ethica Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.2<BR>- Ex-date: Jul-29-2022<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -21.35%, the dividend return was 0%, resulting in a total return of -21.35%.<BR><BR>In the 1 year period, the price return was -23.56%, the dividend return was 0%, leading to a total return of -23.56%.<BR><BR>In the 2 years period, the price return was -29.74%, the dividend return was 0%, which resulted in a total return of -29.74%.<BR><BR>In the 3 years period, the price return was -1.39%, the dividend return was 0.50%, culminating in a total return of -0.89%.<BR><BR>In the 4 years period, the price return was 2.57%, the dividend return was 0.54%, resulting in a total return of 3.11%.<BR><BR>In the 5 years period, the price return was 31.82%, the dividend return was 0.98%, leading to a total return of 32.8%.<BR><BR>Overall, while Zenlabs Ethica Ltd has declared a dividend, the total returns over various periods show significant negative performance, particularly in the shorter terms, with only a modest recovery in the longer term. The dividend yield remains at 0%, indicating limited income generation from dividends relative to the share price.

Who are the peers of the Zenlabs Ethica?

Zenlabs Ethica's peers include International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Esaar (India), Rapid Invest., Gemstone Invest., and Harmony Capital. Management risk varies from excellent at International Ge to below average at Zenlabs Ethica, with Nirlon showing the highest 1-year return at 22.15% and Zenlabs Ethica at -17.80%.

Peers: The peers of Zenlabs Ethica are International Ge, CMS Info Systems, NESCO, SIS, Nirlon, Esaar (India), Rapid Invest., Gemstone Invest., and Harmony Capital.<BR><BR>Quality Snapshot: Excellent management risk is observed at International Ge and the rest have varying ratings. Good management risk is found at CMS Info Systems and Nirlon, while Average management risk is present at NESCO, SIS, and Esaar (India). Below Average management risk is noted at Zenlabs Ethica, Rapid Invest., and Gemstone Invest. Growth is Average at Zenlabs Ethica and Nirlon, while Average growth is also seen at International Ge, with Below Average growth at CMS Info Systems, NESCO, SIS, and Esaar (India). The rest have Below Average growth ratings. Excellent capital structure is noted at International Ge, CMS Info Systems, NESCO, Esaar (India), Rapid Invest., Gemstone Invest., and Disha Resources, while Good capital structure is found at SIS, and Below Average at Nirlon and Zenlabs Ethica.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nirlon at 22.15%, while Rapid Invest. has the lowest return with N/A, and Zenlabs Ethica's 1-year return is -17.80%. Additionally, the peers with negative six-month returns include NESCO, SIS, Rapid Invest., and Disha Resources.

Is Zenlabs Ethica overvalued or undervalued?

As of April 26, 2023, Zenlabs Ethica is considered very expensive and overvalued, with a PE ratio of 21.71, an EV to EBIT of 25.09, a low ROE of 2.59%, and a PEG ratio of 0.00, while its stock has underperformed the Sensex with a return of -21.76% compared to the Sensex's 7.61%.

As of 26 April 2023, the valuation grade for Zenlabs Ethica has moved from does not qualify to very expensive, indicating a significant shift in its valuation outlook. The company is currently assessed as overvalued. Key ratios include a PE ratio of 21.71, an EV to EBIT of 25.09, and a ROE of 2.59%, which highlight its high valuation relative to its earnings and equity returns.<BR><BR>In comparison to its peers, Zenlabs Ethica's PE ratio is notably higher than Life Insurance, which stands at 12.54, and Bajaj Finserv, with a PE of 35.83, indicating that while it is expensive, it is not the highest in its category. The PEG ratio of 0.00 suggests that there is no growth expected, further supporting the overvaluation claim. Additionally, Zenlabs Ethica's stock has underperformed against the Sensex over the past year, with a return of -21.76% compared to the Sensex's 7.61%, reinforcing the notion that the stock may be overpriced at its current valuation.

What is the technical trend for Zenlabs Ethica?

As of May 23, 2025, Zenlabs Ethica's trend is mildly bearish, with mixed indicators showing a mildly bullish weekly MACD but a bearish monthly MACD and daily moving averages.

As of 23 May 2025, the technical trend for Zenlabs Ethica has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands on a monthly basis are bearish, further supporting the overall bearish sentiment. The KST shows a mildly bullish trend weekly but is bearish monthly, indicating mixed signals. The Dow Theory reflects a mildly bullish trend on the weekly chart but shows no trend on the monthly chart. Overall, the current stance is mildly bearish with some mixed indicators, particularly in the weekly time frame.

Who are in the management team of Zenlabs Ethica?

As of March 2022, the management team of Zenlabs Ethica includes Sanjeev Kumar (Managing Director & CEO), Him Jyoti (Director), Ashok Kumar Gupta (Independent Director), Sanjay Dhir (Whole Time Director & CFO), Anurag Malhotra (Independent Director), Kuldeep Singh (Director), Hitesh Popatlal Oswal (Executive Director), and Akshay Saxena (Company Secretary & Compliance Officer). Each member plays a key role in the company's governance and operations.

As of March 2022, the management team of Zenlabs Ethica includes the following members:<BR><BR>1. Sanjeev Kumar - Managing Director & CEO<BR>2. Him Jyoti - Director<BR>3. Ashok Kumar Gupta - Independent Director<BR>4. Sanjay Dhir - Whole Time Director & CFO<BR>5. Anurag Malhotra - Independent Director<BR>6. Kuldeep Singh - Director<BR>7. Hitesh Popatlal Oswal - Executive Director<BR>8. Akshay Saxena - Company Secretary & Compliance Officer<BR><BR>Each member holds a significant position within the company, contributing to its governance and operational management.

Who are the top shareholders of the Zenlabs Ethica?

The top shareholders of Zenlabs Ethica are Preet Remedies Limited with 26.58%, followed by public shareholder Hitesh Popatlal Oswal at 6.79%. Individual investors collectively own 41.03%, with no mutual funds or foreign institutional investors holding shares.

The top shareholders of Zenlabs Ethica include Preet Remedies Limited, which holds the largest share at 26.58%. The highest public shareholder is Hitesh Popatlal Oswal, with a holding of 6.79%. Additionally, individual investors collectively hold 41.03% of the company's shares. There are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company.

How has been the historical performance of Zenlabs Ethica?

Zenlabs Ethica has experienced a decline in net sales and profits from Mar'22 to Mar'25, with net sales dropping from 69.09 Cr to 51.42 Cr and profit after tax decreasing from 1.26 Cr to 0.27 Cr. However, cash flow from operations improved significantly, rising to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24.

Answer:<BR>The historical performance of Zenlabs Ethica shows a declining trend in net sales and profit over the past few years, with net sales decreasing from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25. Operating profit (PBDIT) also saw fluctuations, peaking at 3.04 Cr in Mar'23 before falling to 2.61 Cr in Mar'25. Profit before tax decreased from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax declined from 1.26 Cr in Mar'19 to 0.27 Cr in Mar'25. The earnings per share (EPS) reflected this downward trend, decreasing from 1.94 in Mar'19 to 0.41 in Mar'25. <BR><BR>In terms of assets and liabilities, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, while total liabilities also rose from 31.75 Cr in Mar'21 to 40.38 Cr in Mar'25. The company maintained a consistent share capital of 6.51 Cr over the years, and reserves grew from 0.90 Cr in Mar'20 to 3.92 Cr in Mar'25. Cash flow from operating activities improved to 3.00 Cr in Mar'25 from a negative 9.00 Cr in Mar'24, indicating a recovery in operational cash generation. Overall, while Zenlabs Ethica has experienced challenges in revenue and profit, there are signs of improvement in cash flow from operations.<BR><BR>Breakdown:<BR>Zenlabs Ethica's financial performance has shown a notable decline in net sales, which fell from 69.09 Cr in Mar'22 to 51.42 Cr in Mar'25, reflecting a consistent downward trend over the years. Total operating income mirrored this decline, decreasing from 69.09 Cr to 51.42 Cr in the same period. Operating profit (PBDIT) peaked at 3.04 Cr in Mar'23 but subsequently dropped to 2.61 Cr in Mar'25. Profit before tax also decreased significantly from 1.89 Cr in Mar'19 to 0.43 Cr in Mar'25, while profit after tax fell from 1.26 Cr to 0.27 Cr over the same timeframe. Earnings per share (EPS) declined from 1.94 in Mar'19 to 0.41 in Mar'25, indicating reduced profitability for shareholders. On the balance sheet, total assets increased from 33.65 Cr in Mar'20 to 40.38 Cr in Mar'25, alongside a rise in total liabilities from 31.75 Cr to 40.38 Cr. The company maintained a stable share capital of 6.51 Cr and saw its reserves grow from 0.90 Cr to 3.92 Cr. Notably, cash flow from operating activities improved to 3.00 Cr in Mar'25, recovering from a negative 9.00 Cr in Mar'24, suggesting a positive shift in operational cash generation despite the overall challenges in revenue and profit.

Are Zenlabs Ethica Ltd latest results good or bad?

Zenlabs Ethica Ltd's latest results are largely negative, showing a net profit of ₹0.04 crore with a 20% year-on-year decline, despite a 33.33% sequential growth. Revenue also decreased by 6.89% year-on-year, and the low profit margin and return on equity indicate significant financial challenges.

Zenlabs Ethica Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a net profit of ₹0.04 crore, which reflects a positive sequential growth of 33.33% compared to the previous quarter. However, this figure represents a significant decline of 20% year-on-year, indicating ongoing challenges in profitability.<BR><BR>Revenue for the same quarter was ₹12.43 crore, showing an 8.28% increase quarter-on-quarter, but a concerning 6.89% decrease compared to the same quarter last year. This trend of declining revenues is troubling, as it suggests the company is struggling to maintain its market position.<BR><BR>The profit after tax (PAT) margin remains extremely low at 0.32%, which provides little cushion against operational disruptions. Additionally, the return on equity (ROE) has dropped to a mere 2.37%, indicating severe capital inefficiency and a lack of value creation for shareholders.<BR><BR>Overall, while there are slight improvements in sequential performance, the year-on-year declines in both revenue and profit, coupled with very thin margins and weak returns on equity, suggest that Zenlabs Ethica is facing significant operational and financial challenges. Investors should approach the company with caution given these results.

Should I buy, sell or hold Zenlabs Ethica Ltd?

Why is Zenlabs Ethica Ltd falling/rising?

As of 08-May, Zenlabs Ethica Ltd's stock is declining, down 3.29% today and 6.87% over the last two days. Despite positive long-term performance, it underperforms its sector and is below the 200-day moving average, indicating potential weakness.

As of 08-May, Zenlabs Ethica Ltd's stock price is currently falling, with a change of -0.83, which represents a decline of 3.29%. This downward movement is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total decline of 6.87% during this period. <BR><BR>Despite some positive performance in the longer term, such as a 22.56% increase year-to-date and a 14.72% rise over the past month, the stock has underperformed today compared to its sector by 1.71%. Additionally, while the stock's price is above its 5-day, 20-day, 50-day, and 100-day moving averages, it remains below the 200-day moving average, indicating a potential longer-term weakness.<BR><BR>Investor participation has seen an increase, with a delivery volume of 6.09k on May 7, which is up by 2.95% compared to the 5-day average. However, this rise in participation has not translated into positive price movement, as the stock continues to experience a decline. Overall, the combination of recent consecutive falls, underperformance relative to the sector, and the current price being below the 200-day moving average contributes to the stock's falling price.

Which are the latest news on Zenlabs Ethica?